Meadow Brook Investment Advisors LLC Syndax Pharmaceuticals Inc Transaction History
Meadow Brook Investment Advisors LLC
- $112 Billion
- Q2 2025
Shares
2 transactions
Others Institutions Holding SNDX
# of Institutions
249Shares Held
101MCall Options Held
1.27MPut Options Held
1.28M-
Kynam Capital Management, LP Princeton, NJ8.52MShares$111 Million9.53% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$103 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.8MShares$75.2 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$65.3 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.07MShares$52.7 Million3.84% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $734M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...